- Home
- OPEN vs LEGN Comparison
OPEN vs LEGN Comparison
Compare OPEN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPEN
- LEGN
- Stock Information
- Founded
- OPEN 2014
- LEGN 2014
- Country
- OPEN United States
- LEGN United States
- Employees
- OPEN N/A
- LEGN N/A
- Industry
- OPEN Real Estate
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- OPEN Finance
- LEGN Health Care
- Exchange
- OPEN Nasdaq
- LEGN Nasdaq
- Market Cap
- OPEN 5.9B
- LEGN 5.9B
- IPO Year
- OPEN N/A
- LEGN 2020
- Fundamental
- Price
- OPEN $7.88
- LEGN $27.67
- Analyst Decision
- OPEN Sell
- LEGN Strong Buy
- Analyst Count
- OPEN 4
- LEGN 13
- Target Price
- OPEN $1.88
- LEGN $72.92
- AVG Volume (30 Days)
- OPEN 149.9M
- LEGN 1.8M
- Earning Date
- OPEN 11-06-2025
- LEGN 11-12-2025
- Dividend Yield
- OPEN N/A
- LEGN N/A
- EPS Growth
- OPEN N/A
- LEGN N/A
- EPS
- OPEN N/A
- LEGN N/A
- Revenue
- OPEN $4,719,000,000.00
- LEGN $909,045,000.00
- Revenue This Year
- OPEN N/A
- LEGN $68.68
- Revenue Next Year
- OPEN N/A
- LEGN $48.49
- P/E Ratio
- OPEN N/A
- LEGN N/A
- Revenue Growth
- OPEN N/A
- LEGN 74.75
- 52 Week Low
- OPEN $0.51
- LEGN $25.71
- 52 Week High
- OPEN $10.87
- LEGN $45.30
- Technical
- Relative Strength Index (RSI)
- OPEN 52.39
- LEGN 32.95
- Support Level
- OPEN $6.14
- LEGN $25.71
- Resistance Level
- OPEN $8.08
- LEGN $29.39
- Average True Range (ATR)
- OPEN 0.94
- LEGN 1.53
- MACD
- OPEN -0.02
- LEGN -0.27
- Stochastic Oscillator
- OPEN 62.38
- LEGN 25.03
About OPEN Opendoor Technologies Inc
Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.